EPO mRNAs have been designed to produce high expression level of Erythropoietin protein. OZB mRNAs are produced by in vitro transcription. mRNAs are stabilised at the 5’ end by modified nucleotides capping (Cap1) and contain a poly(A) tail at the 3’ end. Sequences have been optimized to yield improved stability and performance. Available as unmodified or modified versions: modified with 5-methoxyuridine (5moU replaces U) to reduce innate immune responses or modified with N1-methyl-pseudouridine (N1-mψ) to reduce innate immune response.

• Shipped on drug ice - storage at -80°C